CHARGED ALPHA
Stock Analysis
HCA Unclassified Latest YouTube: Q2 2026

HCA

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

HCA Healthcare Stock: It Beat Q2 but CUT Its Guidance — So Why We Say BUY

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q2 2026
Podcast available
Yes
Current price
$382.19
+2.76 (+0.73%)
Trailing / Forward P/E
13.17x
Forward: 11.70x
Market cap / Volume
Volume:
Revenue / Earnings Growth
4.3%
Earnings: 10.9%
Margins
15.0% op
Gross: 41.6% · Net: 8.9%
Balance sheet
0.83x current
Debt / Equity: —
52-week range / Beta
$330.00 - $556.52
Beta: 1.13
Analyst target
$469.10
Upside: 22.7%
Cash / shareholder return
6.75% FCF yield
Dividend yield: 0.83%

Company context

Industry: Medical Care Facilities
Country: United States
Employees:
Price to book: -13.49x
Return on equity:
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and acute care hospitals offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

Price chart

Market context for HCA

Competitive view

HCA vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

HCA latest YouTube video thumbnail YouTube
HCA
HCA
Latest video
Q2 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Danaher Corporation latest YouTube video thumbnail YouTube
Danaher Corporation
DHR
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
ADBE latest YouTube video thumbnail YouTube
ADBE
ADBE
Latest video
Q2 FY2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
HCA
$84.78B
HCA
DHR
$134.62B
Danaher Corporation
ADBE
$89.48B
ADBE
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
HCA
13.2x
HCA
DHR
34.2x
Danaher Corporation
ADBE
12.9x
ADBE
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
HCA
11.7x
HCA
DHR
20.7x
Danaher Corporation
ADBE
8.2x
ADBE
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
HCA
4.3%
HCA
DHR
5.5%
Danaher Corporation
ADBE
12.7%
ADBE
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
HCA
10.9%
HCA
DHR
59.7%
Danaher Corporation
ADBE
7.9%
ADBE
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
HCA
15.0%
HCA
DHR
19.8%
Danaher Corporation
ADBE
35.3%
ADBE
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
HCA
41.6%
HCA
DHR
58.8%
Danaher Corporation
ADBE
89.4%
ADBE
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
HCA
8.9%
HCA
DHR
15.9%
Danaher Corporation
ADBE
28.7%
ADBE
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
HCA
HCA
DHR
7.6%
Danaher Corporation
ADBE
63.0%
ADBE
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
HCA
6.8%
HCA
DHR
3.2%
Danaher Corporation
ADBE
10.3%
ADBE
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
HCA
HCA
DHR
52.97x
Danaher Corporation
ADBE
61.44x
ADBE
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
HCA
0.83x
HCA
DHR
1.65x
Danaher Corporation
ADBE
0.75x
ADBE
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
HCA
1.13
HCA
DHR
0.82
Danaher Corporation
ADBE
1.43
ADBE
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
HCA
0.8%
HCA
DHR
0.8%
Danaher Corporation
ADBE
ADBE
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
HCA
22.7%
HCA
DHR
18.9%
Danaher Corporation
ADBE
19.8%
ADBE

Related research

Non-quarter videos featuring HCA

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections
Shorts and Clips 2026-07-24

HCA Beat Q2, Then CUT Guidance — Buy or Value Trap? #Shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

Episode timeline

Episode archive for HCA

Each row is one earnings episode with every verified platform link available.

Q2 2026
Episode live
Published youtube podcast complete
HCA Healthcare Stock: It Beat Q2 but CUT Its Guidance — So Why We Say BUY
Quarterly earnings-analysis entry for HCA. Use the links on the right to open the video or podcast episode.